Histogenics Corp (NASDAQ:HSGX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, AnalystRatings.NET reports.
According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
Several other equities research analysts have also recently issued reports on the stock. Cowen and Company reduced their price target on shares of Histogenics Corp from $17.00 to $12.50 and set an “outperform” rating for the company in a report on Friday, November 13th. Canaccord Genuity reduced their price objective on shares of Histogenics Corp from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 13th. Needham & Company LLC dropped their target price on shares of Histogenics Corp from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, November 13th. Finally, BTIG Research downgraded shares of Histogenics Corp from a “buy” rating to a “neutral” rating in a report on Friday, November 13th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $12.13. 